Clinical Trial: Sphingolipid Metabolic Reprogramming Drives the JUN–RAC1 Signaling Axis in Brain Metastasis of EGFR-Mutant Lung Adenocarcinoma (China)

China, Sept. 8 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Sphingolipid Metabolic Reprogramming Drives the JUN–RAC1 Signaling Axis in Brain Metastasis of EGFR-Mutant Lung Adenocarcinoma'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600131836

Registration Time: 2026/09/07

Type: Observational study

Primary Sponsor: Chongqing University Three Gorges Hospital（Chongqing Three Gorges Central Hospital）

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=339685

Published by HT Digital Content Services with permission from Health Daily Digest....